Results 231 to 240 of about 107,253 (254)
Some of the next articles are maybe not open access.
Influence of proteasome inhibitors on apoptosis
Current Opinion in Clinical Nutrition & Metabolic Care, 2006Proteasome inhibitors are a novel class of drugs that alter normal cellular control of apoptosis. As such, they are being investigated as novel therapies to alter uncontrolled cellular proliferation and treat cancers. This review explores new information about how the proteasome regulates apoptosis and how proteasome inhibitors can be exploited as anti-
Stacey R, Vlahakis, Andrew D, Badley
openaire +2 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2010
The 26S proteasome is a multicatalytic enzyme responsible for degradation of a large fraction of intracellular proteins. Targeting the proteasome activity is a rational and novel strategy for cancer therapy that can lead to cell death for transformed cells.
Yasushi, Saeki +2 more
openaire +1 more source
The 26S proteasome is a multicatalytic enzyme responsible for degradation of a large fraction of intracellular proteins. Targeting the proteasome activity is a rational and novel strategy for cancer therapy that can lead to cell death for transformed cells.
Yasushi, Saeki +2 more
openaire +1 more source
Nihon rinsho. Japanese journal of clinical medicine, 2010
The ubiquitin-proteasome pathway plays an important role in the regulation of cellular proteins with regard to cell cycle control, transcription, apoptosis, cell adhesion, angiogenesis and tumor growth. Proteasome inhibition is a novel approach to the treatment of solid tumors.
Masahiro, Yamamura +2 more
openaire +1 more source
The ubiquitin-proteasome pathway plays an important role in the regulation of cellular proteins with regard to cell cycle control, transcription, apoptosis, cell adhesion, angiogenesis and tumor growth. Proteasome inhibition is a novel approach to the treatment of solid tumors.
Masahiro, Yamamura +2 more
openaire +1 more source
Proteasome inhibitors in Waldenström macroglobulinemia
Blood, 2013In this issue of Blood , Dimopoulos and colleagues report on a prospective multicenter clinical trial conducted by the European Myeloma Network (EMN) that evaluated the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with untreated, symptomatic Waldenstrom macroglobulinemia (WM ...
openaire +2 more sources
Proteasome inhibitors in lung cancer
Critical Reviews in Oncology/Hematology, 2006Proteasome inhibition is a novel therapeutic approach that is being investigated in non-small cell and small cell lung cancer (NSCLC and SCLC). Proteasome inhibition affects a range of intracellular signals and disrupts the levels of numerous proteins, causing apoptosis via multiple pathways.
openaire +2 more sources
Proteasome Inhibitors in Cancer Therapy
Current Drug Targets, 2009The ubiquitin-proteasome pathway is involved in intracellular protein turnover and plays an essential function in many cellular processes, thus contributing to cellular homeostasis. The observation that proteasome inhibitors are able to induce apoptosis preferentially in tumor cells opened the way to their use as potential drugs.
openaire +2 more sources
Oncology (Williston Park, N.Y.), 2008
Dharminder Chauhan, Kenneth C. Anderson
openaire +3 more sources
Dharminder Chauhan, Kenneth C. Anderson
openaire +3 more sources
Potent Inhibitors of Proteasome
Journal of Medicinal Chemistry, 1995M, Iqbal +7 more
openaire +2 more sources
La Revue de medecine interne, 2005
Proteasome is involved in cell cycle and apoptosis regulation. Its deregulation could participate to oncogenesis.Bortezomib is the first proteasome inhibitor to reach clinical development. Its main adverse events are asthenia, thrombocytopenia and cumulative neurotoxicity which can limits long term use.
openaire +1 more source
Proteasome is involved in cell cycle and apoptosis regulation. Its deregulation could participate to oncogenesis.Bortezomib is the first proteasome inhibitor to reach clinical development. Its main adverse events are asthenia, thrombocytopenia and cumulative neurotoxicity which can limits long term use.
openaire +1 more source
Nihon rinsho. Japanese journal of clinical medicine, 2014
The ubiquitin-proteasome system plays an essential role in degradation of eukaryotic intracellular protein, including cell cycle regulation, cell growth and proliferation, and survival. Cancer cells generally have higher level of proteasome activity compared with normal cells, suggesting proteasome inhibition could be therapeutic target in oncology ...
openaire +1 more source
The ubiquitin-proteasome system plays an essential role in degradation of eukaryotic intracellular protein, including cell cycle regulation, cell growth and proliferation, and survival. Cancer cells generally have higher level of proteasome activity compared with normal cells, suggesting proteasome inhibition could be therapeutic target in oncology ...
openaire +1 more source